Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458516 | 0.86 | TSHR (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL10200652 | 0.85 | TSHR (0.46) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24718640 | 0.82 | TSHR (0.38) | TSHR | |
| SCHEMBL29333443 | 0.82 | TSHR (0.32) | TSHRHRH3 | |
| SCHEMBL117165 | 0.82 | GRIN2D (0.46) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL17886904 | 0.81 | CYP3A4 (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL15781123 | 0.79 | GRIN2D (0.45) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL10200636 | 0.79 | CYP2D6 (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL22871684 | 0.79 | TSHR (0.33) | TSHR | |
| SCHEMBL19226582 | 0.79 | TSHR (0.37) | TSHRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230250077-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250077-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20140213570-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-8729263-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2014-05-20 | — | — | US | disclosed |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, MTOR, PIK3C2A | GRIN2D 3345/4885GRIN3B 2287/4885CHRM2 4090/4885 |
| US-20140213570-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | GRIN2D 2662/4885GRIN3B 2995/4885CHRM2 4159/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | GRIN2D 3361/4885GRIN3B 2874/4885CHRM2 2837/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | GRIN2D 569/4885GRIN3B 31/4885CHRM2 2158/4885 |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, SF3B5 | GRIN2D 2662/4885GRIN3B 2995/4885CHRM2 4159/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | GRIN2D 3132/4885GRIN3B 3401/4885CHRM2 3020/4885 |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | GRIN2D 4599/4885GRIN3B 3510/4885CHRM2 4641/4885 |
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | BTK, SYK, LCK | GRIN2D 4394/4885GRIN3B 2203/4885CHRM2 4488/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | GRIN2D 3175/4885GRIN3B 1680/4885CHRM2 4878/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | GRIN2D 3324/4885GRIN3B 3551/4885CHRM2 4561/4885 |
| US-20230250077-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | GLP1R, HADHB, SUCNR1 | GRIN2D 3172/4885GRIN3B 3909/4885CHRM2 4210/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | GRIN2D 999/4885GRIN3B 1856/4885CHRM2 4569/4885 |
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | GRIN2D 3752/4885GRIN3B 3011/4885CHRM2 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.